Prevalence of immunomodulator use as combination therapy with vedolizumab or ustekinumab in inflammatory bowel disease.

Megan K LutzFreddy CalderaKatie SchroederDerek GazisJulie M CrawfordMillie D LongEdward L Barnes

Published in: Clinical and translational gastroenterology (2023)

Combination therapy with vedolizumab or ustekinumab was common and was associated with perianal disease and greater exposure to other biologics, although the practice is decreasing with time. Further data are needed to determine efficacy and safety of combination therapy in patients initiating vedolizumab or ustekinumab for IBD.

Keyphrases

combination therapy
ulcerative colitis
patients with inflammatory bowel disease
primary care
healthcare
risk factors
electronic health record
big data
quality improvement
machine learning